Provectus Pharmaceuticals to Present at "3rd Annual Cancer Immunotherapy: A Long-Awaited Reality" Co
Provectus Pharmaceuticals to Present at "3rdAnnual Cancer Immunotherapy: A Long-Awaited Reality" Conference on October 4, 2012
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will be presenting at the 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality Conference" on October 4, 2012 at 11:30 a.m. EDT at the New York Academy of Medicine in New York City.
Craig Dees, PhD., Chairman and Chief Executive Officer of Provectus will discuss PV-10's immunologic potential in treating melanoma and other cancer indications including liver, pancreatic and colorectal cancer.
PV-10 is Provectus's novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, thereby reducing potential for systemic side effects.
The presentation will be webcast and archived for future viewing. Further information about the conference and the webcast can be found at the following link: www.regonline.com/mdb2012
About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP - Investor Relations
Bill Gordon, SVP - Media Relations
212-564-4700
KEYWORDS: United States North America New York Tennessee
INDUSTRY KEYWORDS:
The article Provectus Pharmaceuticals to Present at "3rd Annual Cancer Immunotherapy: A Long-Awaited Reality" Conference on October 4, 2012 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
